Gene therapy successfully corrects genetic defect in alpha-1 antitrypsin deficiency
In a landmark achievement in the field of genetic medicine, researchers have reported the very first published case in a peer-reviewed journal of a successful clinical treatment of a patient with alpha-1 antitrypsin deficiency (PiZZ) using in vivo gene therapy.
Read original article on The Medical News →Related news
-
Can Australia's social welfare system handle future aged care needs?
United Kingdom
-
Vitamin C supplements during pregnancy may support infant emotional health
United Kingdom
-
Tumor mutations may help predict relapse risk in childhood leukemia
United Kingdom
-
Toddler snacks pulled from Costco, Target, Walmart and other stores over choking danger
United Kingdom
-
Worldwide survey reveals declining mental well-being among young people
United Kingdom
-
Scientists estimate drownings cost the UK almost £1 billion a year
United Kingdom
-
Study identifies molecular links between menopause and brain aging
United Kingdom
-
Natural tooth protein could pave way for regenerative dental treatments
United Kingdom